Gilead Virus Treatment Is Promising But No Silver Bullet Yet

Gilead Virus Treatment Is Promising But No Silver Bullet Yet

Sam Fazeli, Director of Research: EMEA for Bloomberg Intelligence, on Gilead's positive trial for a potential coronavirus treatment. Lisa Shalett, Chief Investment Officer: Wealth Management for Morgan Stanley, discusses why she wants clients to avoid S&P indices and to actively manage stock picks. David Garrity, Chief Market Strategist for Laidlaw & Co, and Partner at BTblock, discusses Google, Facebook and Big Tech earnings. Brooke Sutherland, Bloomberg Opinion Industrials columnist, on the stark reality for Boeing.

See omnystudio.com/listener for privacy information.

Episoder(3351)

Big Mistake To Not Enlist Europe Against China: Rhodes (Podcast)

Big Mistake To Not Enlist Europe Against China: Rhodes (Podcast)

"Banker to the World" Bill Rhodes, President and CEO of William Rhodes Global Advisors, on the lack of a substantive China trade deal for the U.S. Jason Schenker, President of Prestige Economics and a...

1 Jul 201931min

GOP Strategist Heye Warns Dems Lurching Too Far Left

GOP Strategist Heye Warns Dems Lurching Too Far Left

Doug Heye, former RNC Communications Director and Republican Strategist, unpacks the second night of Democratic debates.  Maria Considine King, Senior Vice President, Practice Management at Commonweal...

28 Jun 201926min

Ford Moves In Right Direction With Euro Job Cuts: Kudla

Ford Moves In Right Direction With Euro Job Cuts: Kudla

David Kudla, CEO and Chief Investment Strategist at Mainstay Capital Management, on Ford eliminating 20% of its workforce across Europe. Chris Lu, Former Deputy Secretary of Labor and Senior Fellow at...

27 Jun 201927min

Little Upside Left in U.S. Junk Bonds: Diamond Hill

Little Upside Left in U.S. Junk Bonds: Diamond Hill

Bill Zox, CIO of Fixed income at Diamond Hill Capital Management, to discuss why there's little upside left in the high yield space. Leland Miller, CEO of China Beige Book International, on China Beig...

26 Jun 201928min

Allergan Is A Short-Term Cosmetic Fix For AbbVie: Nisen

Allergan Is A Short-Term Cosmetic Fix For AbbVie: Nisen

Max Nisen, Bloomberg Opinion health care columnist, on AbbVie buying Botox maker Allergan for $63 billion. CoinShares Chairman Danny Masters discusses the bitcoin rally and Facebook's new Libra crypto...

25 Jun 201925min

Private Equity Fees Are Ripe For The ’Vanguard Effect’

Private Equity Fees Are Ripe For The ’Vanguard Effect’

Eric Balchunas, Senior ETF Analyst for Bloomberg Intelligence, on Vanguard considering offering private equity to investors. Francis Greenburger, Time Equities Chairman & CEO, discusses how the recent...

24 Jun 201927min

Fed's Williams Is Trying to Clean Up Powell's Error (Podcast)

Fed's Williams Is Trying to Clean Up Powell's Error (Podcast)

Phil Orlando, Chief Equity Market Strategist at Federated Investors, on markets, the Fed and current investment strategy.  Clint Watts, Distinguished Research Fellow at the Foreign Policy Research Ins...

21 Jun 201929min

Slack CEO, CFO On Why They Went With A Direct Listing

Slack CEO, CFO On Why They Went With A Direct Listing

Mandeep Singh, Senior Tech Industry Analyst for Bloomberg Intelligence, on Slack going public in a direct listing, and Slack CEO Stewart Butterfield and CFO Allen Shim speak from the NYSE with Emily C...

20 Jun 201928min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
e24-podden
finansredaksjonen
pengepodden-2
rss-sunn-okonomi
pengesnakk
morgenkaffen-med-finansavisen
tid-er-penger-en-podcast-med-peter-warren
utbytte
stormkast-med-valebrokk-stordalen
livet-pa-veien-med-jan-erik-larssen
rss-markedspuls-2
liberal-halvtime
okonomiamatorene
lederpodden
rss-investering-gjort-enkelt